Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Respironics

This article was originally published in The Gray Sheet

Executive Summary

Expansion of the firm's Japan presence via acquisition of respiratory home care and hospital product provider Fuji RC for $12 mil. in cash is announced May 31. The deal includes assumption of about $11 mil. in debt and provisions for additional payments based on operating performance over the next four years. The Japanese firm will add about $15-18 mil. to Respironics' annual revenues and be "modestly accretive" to earnings, adding about $0.01 per share in the second half of fiscal 2003, Respironics notes...

You may also be interested in...



Respironics Raises UK Profile: Distributor Purchase Yields Drug Delivery Tech

Respironics' planned integration of UK distributor Profile Therapeutics includes access to Profile's Prodose inhaled aerosol drug delivery technology

Oxford/AstraZeneca Vaccine Shows 70% Efficacy As Company Prepares Approval Filings

Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.

EBITDA Margin Of 33% Not Sustainable, Krka Underlines

Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel